• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PPARs 的激活调节了人源 CD14+单核细胞来源的破骨细胞中的信号通路和调控基因的表达。

Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes.

机构信息

Department of Physiology, University of Pretoria, Pretoria 0001, South Africa.

School of Health Sciences, College of Health, Massey University, Palmerston North 4442, New Zealand.

出版信息

Int J Mol Sci. 2019 Apr 11;20(7):1798. doi: 10.3390/ijms20071798.

DOI:10.3390/ijms20071798
PMID:30979019
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6479901/
Abstract

Osteoclasts are the sole bone resorbing cell in the body and their over activity is key in the development of osteoporosis. Osteoclastogenesis is mediated by receptor activator of nuclear factor κB ligand (RANKL) signalling pathways. Unsaturated fatty acids (UFA) are known to inhibit osteoclastogenesis by targeting RANKL signalling. However, the mechanisms of action remain unclear. Peroxisome proliferator activated receptors (PPARs) are a family of nuclear receptors, with three known isoforms (PPAR-α, PPAR-β/δ and PPAR-γ), that are known to bind UFAs and are expressed in osteoclasts. In this study, we aimed to determine how different families of UFAs activate PPARs and how PPAR activation influences osteoclast signalling. Human CD14+ monocytes were seeded into cluster plates with RANKL and macrophage colony stimulating factor (M-CSF) in the presence of PPAR agonists or different types of UFAs. All the PPAR agonists were shown to upregulate the activity of their respective receptors. Polyunsaturated fatty acids increased PPAR-α to a greater extent than monounsaturated fatty acids (MUFAs), which favoured PPAR-β/δ activation. All PPAR agonists inhibited osteoclastogenesis. The activation of RANKL signalling pathways and expression of key osteoclast genes were downregulated by PPAR agonists. This study reveals that PPAR activation can inhibit osteoclastogenesis through modulation of RANKL signalling.

摘要

破骨细胞是体内唯一具有骨吸收功能的细胞,其过度活跃是骨质疏松症发展的关键。破骨细胞的形成是由核因子κB 受体激活剂配体(RANKL)信号通路介导的。已知不饱和脂肪酸(UFA)通过靶向 RANKL 信号通路来抑制破骨细胞的形成。然而,其作用机制尚不清楚。过氧化物酶体增殖物激活受体(PPARs)是一类核受体,有三种已知的亚型(PPAR-α、PPAR-β/δ 和 PPAR-γ),已知它们可以与 UFA 结合并在破骨细胞中表达。在这项研究中,我们旨在确定不同类型的 UFA 如何激活 PPARs,以及 PPAR 激活如何影响破骨细胞信号转导。将人 CD14+单核细胞接种到含有 RANKL 和巨噬细胞集落刺激因子(M-CSF)的聚类板中,并在 PPAR 激动剂或不同类型的 UFA 存在的情况下进行培养。所有的 PPAR 激动剂都被证明能上调其相应受体的活性。多不饱和脂肪酸(PUFAs)比单不饱和脂肪酸(MUFAs)更能上调 PPAR-α的活性,而 MUFAs 则更有利于 PPAR-β/δ 的激活。所有的 PPAR 激动剂都抑制了破骨细胞的形成。RANKL 信号通路的激活和关键破骨细胞基因的表达也被 PPAR 激动剂下调。这项研究揭示了 PPAR 激活可以通过调节 RANKL 信号转导来抑制破骨细胞的形成。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/d82f043ba5b6/ijms-20-01798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/d7a5451ee410/ijms-20-01798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/984dd02d2841/ijms-20-01798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/8763ff1f7026/ijms-20-01798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/35875efe9d20/ijms-20-01798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/cefa243457f3/ijms-20-01798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/d82f043ba5b6/ijms-20-01798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/d7a5451ee410/ijms-20-01798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/984dd02d2841/ijms-20-01798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/8763ff1f7026/ijms-20-01798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/35875efe9d20/ijms-20-01798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/cefa243457f3/ijms-20-01798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85bf/6479901/d82f043ba5b6/ijms-20-01798-g006.jpg

相似文献

1
Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes.PPARs 的激活调节了人源 CD14+单核细胞来源的破骨细胞中的信号通路和调控基因的表达。
Int J Mol Sci. 2019 Apr 11;20(7):1798. doi: 10.3390/ijms20071798.
2
PPAR agonists modulate human osteoclast formation and activity in vitro.过氧化物酶体增殖物激活受体激动剂在体外可调节人破骨细胞的形成和活性。
Bone. 2007 Jan;40(1):149-59. doi: 10.1016/j.bone.2006.07.029. Epub 2006 Sep 28.
3
Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.过氧化物酶体增殖物激活受体γ的激活部分通过抑制单核细胞趋化蛋白-1的表达来抑制人外周血单核细胞中肿瘤坏死因子-α介导的破骨细胞分化。
Bone. 2008 Apr;42(4):765-74. doi: 10.1016/j.bone.2007.11.016. Epub 2007 Dec 15.
4
Free fatty acid receptor 4-β-arrestin 2 pathway mediates the effects of different classes of unsaturated fatty acids in osteoclasts and osteoblasts.游离脂肪酸受体 4-β-arrestin 2 通路介导不同类不饱和脂肪酸在破骨细胞和骨细胞中的作用。
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):281-289. doi: 10.1016/j.bbalip.2018.12.009. Epub 2018 Dec 19.
5
BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.骨唾液蛋白(BSP)和核因子κB受体活化因子配体(RANKL)协同诱导破骨细胞生成和骨吸收。
J Bone Miner Res. 2005 Sep;20(9):1669-79. doi: 10.1359/JBMR.050511. Epub 2005 May 16.
6
Hydroxy monounsaturated fatty acids as agonists for peroxisome proliferator-activated receptors.羟基单不饱和脂肪酸作为过氧化物酶体增殖物激活受体的激动剂。
Biol Pharm Bull. 2010;33(5):854-61. doi: 10.1248/bpb.33.854.
7
RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.RGS18通过调节酸敏感OGR1/NFAT信号通路,作为破骨细胞生成的负调节因子。
J Bone Miner Res. 2007 Oct;22(10):1612-20. doi: 10.1359/jbmr.070612.
8
Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.衰老会增加基质/成骨细胞诱导的破骨细胞生成,并改变小鼠体内破骨细胞前体细胞库。
J Bone Miner Res. 2005 Sep;20(9):1659-68. doi: 10.1359/JBMR.050503. Epub 2005 May 2.
9
Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.野葛抑制 RANKL 介导的破骨细胞分化通过下调 CREB/PGC1β/c-Fos/NFATc1 信号通路。
Am J Chin Med. 2017;45(8):1725-1744. doi: 10.1142/S0192415X17500938. Epub 2017 Nov 9.
10
Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.一种可分化为破骨细胞的人外周血单核细胞亚群的鉴定。
Arthritis Res Ther. 2006;8(5):R152. doi: 10.1186/ar2046.

引用本文的文献

1
Per- and polyfluorinated substances (PFAS) promote osteoclastogenesis and bone loss through PPARα activation.全氟和多氟烷基物质(PFAS)通过激活过氧化物酶体增殖物激活受体α(PPARα)促进破骨细胞生成和骨质流失。
Toxicol Rep. 2025 Jun 20;15:102071. doi: 10.1016/j.toxrep.2025.102071. eCollection 2025 Dec.
2
Lipid metabolism in age-related musculoskeletal disorders: insights into sarcopenia and osteoporosis.年龄相关性肌肉骨骼疾病中的脂质代谢:对肌肉减少症和骨质疏松症的见解
BMC Biol. 2025 Aug 22;23(1):265. doi: 10.1186/s12915-025-02383-9.
3
Bone metabolism - an underappreciated player.

本文引用的文献

1
Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.过氧化物酶体增殖物激活受体 (PPAR)γ 激动剂作为肿瘤组织的主要调节剂。
Int J Mol Sci. 2018 Nov 9;19(11):3540. doi: 10.3390/ijms19113540.
2
PPAR Agonists and Metabolic Syndrome: An Established Role?过氧化物酶体增殖物激活受体激动剂与代谢综合征:已有定论?
Int J Mol Sci. 2018 Apr 14;19(4):1197. doi: 10.3390/ijms19041197.
3
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
骨代谢——一个未得到充分重视的因素。
NPJ Metab Health Dis. 2024 Jul 1;2(1):12. doi: 10.1038/s44324-024-00010-9.
4
Exploring the Effects of Zingerone on Differentiation and Signalling Pathways in Bone Cell Lines.探索姜辣素对骨细胞系分化及信号通路的影响。
Metabolites. 2024 Dec 9;14(12):693. doi: 10.3390/metabo14120693.
5
Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships.脂质代谢与骨稳态之间的相互作用:探索复杂的信号关系。
Research (Wash D C). 2024 Aug 20;7:0447. doi: 10.34133/research.0447. eCollection 2024.
6
Identification of steroid-induced osteonecrosis of the femoral head biomarkers based on immunization and animal experiments.基于免疫和动物实验鉴定激素诱导性股骨头坏死的生物标志物。
BMC Musculoskelet Disord. 2024 Jul 29;25(1):596. doi: 10.1186/s12891-024-07707-4.
7
Nutraceuticals and Functional Foods: A Comprehensive Review of Their Role in Bone Health.营养保健品和功能性食品:其在骨骼健康中的作用的综合评价。
Int J Mol Sci. 2024 May 28;25(11):5873. doi: 10.3390/ijms25115873.
8
Diet, lifestyle factors, comorbidities, and hepatocellular carcinoma risk in a middle eastern country: a case-control study.饮食、生活方式因素、合并症与中东国家肝细胞癌风险的病例对照研究。
BMC Cancer. 2024 Jun 6;24(1):694. doi: 10.1186/s12885-024-12409-0.
9
Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/ABCG2 in epithelial ovarian cancer.富含脂肪细胞的微环境通过上调过氧化物酶体增殖物激活受体γ/ABCG2 促进上皮性卵巢癌的化疗耐药性。
Int J Mol Med. 2024 Apr;53(4). doi: 10.3892/ijmm.2024.5361. Epub 2024 Mar 1.
10
Association between fatty acids intake and bone mineral density in adults aged 20-59: NHANES 2011-2018.20 - 59岁成年人脂肪酸摄入量与骨密度之间的关联:2011 - 2018年美国国家健康与营养检查调查(NHANES)
Front Nutr. 2023 Mar 17;10:1033195. doi: 10.3389/fnut.2023.1033195. eCollection 2023.
贝特类药物在高甘油三酯血症和低高密度脂蛋白胆固醇血症患者中的疗效和安全性:一项多中心、安慰剂对照、双盲、随机试验。
J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7.
4
Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy.过氧化物酶体增殖物激活受体(PPARs)是癌症治疗的潜在药物靶点。
Oncotarget. 2017 Jul 27;8(36):60704-60709. doi: 10.18632/oncotarget.19610. eCollection 2017 Sep 1.
5
Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.棕榈油酸通过抑制NF-κB和MAPK信号通路来抑制RANKL诱导的破骨细胞生成和骨吸收。
Nutrients. 2017 Apr 28;9(5):441. doi: 10.3390/nu9050441.
6
PPARδ promotes tumor progression via activation of Glut1 and SLC1-A5 transcription.过氧化物酶体增殖物激活受体δ(PPARδ)通过激活葡萄糖转运蛋白1(Glut1)和溶质载体家族1成员A5(SLC1-A5)的转录来促进肿瘤进展。
Carcinogenesis. 2017 Jul 1;38(7):748-755. doi: 10.1093/carcin/bgx035.
7
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.新型选择性过氧化物酶体增殖物激活受体α调节剂(SPPARMα)K-877与他汀类药物联合治疗的疗效和安全性:两项针对血脂异常患者的随机、双盲、安慰剂对照临床试验。
Atherosclerosis. 2017 Jun;261:144-152. doi: 10.1016/j.atherosclerosis.2017.03.032. Epub 2017 Mar 24.
8
Non-insulin anti-diabetic drugs: An update on pharmacological interactions.非胰岛素类抗糖尿病药物:药理相互作用的最新进展
Pharmacol Res. 2017 Jan;115:14-24. doi: 10.1016/j.phrs.2016.11.005. Epub 2016 Nov 9.
9
PPAR-γ regulates pharmacological but not physiological or pathological osteoclast formation.过氧化物酶体增殖物激活受体γ(PPAR-γ)调节药物性破骨细胞形成,但不调节生理性或病理性破骨细胞形成。
Nat Med. 2016 Nov 8;22(11):1203-1205. doi: 10.1038/nm.4208.
10
Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1.黄芪甲苷,一种天然的过氧化物酶体增殖物激活受体 γ 激动剂,通过抑制 BACE1 减少阿尔茨海默病中的 Aβ 产生。
Mol Neurobiol. 2017 May;54(4):2939-2949. doi: 10.1007/s12035-016-9874-6. Epub 2016 Mar 29.